Specialty Drug Management for Employer Health Plans: A Mid-Market Guide

For most employer health plans serving 20 to 200 employees, the line item that drives more budget anxiety than any other is specialty pharmacy. A single employee on a high-cost biologic for rheumatoid arthritis, multiple sclerosis, or a cancer diagnosis can generate $100,000 to $500,000 in annual claims. Gene therapies approved in the last three years carry price tags of $1 million or more per patient. And unlike hospital or surgical claims that occur infrequently, specialty medications are ongoing, monthly costs that accumulate predictably throughout the plan year.

The challenge for mid-market employers is that the specialty pharmacy cost problem was largely designed for large employer solutions. Fortune 500 companies have dedicated pharmacy benefit consultants, proprietary specialty pharmacy arrangements, and population health infrastructure that smaller employers cannot replicate at scale. But the economics of specialty drug management have shifted enough that well-designed programs are now accessible and financially meaningful for groups as small as 25 enrolled lives.

This guide explains what specialty drug management actually involves, how costs accumulate in typical mid-market plans, and which specific interventions produce the best return relative to implementation complexity for employers in the 25 to 200 employee range.

Why Specialty Pharmacy Costs Are Structured the Way They Are

Specialty drugs are defined by a combination of characteristics: they typically require special handling (refrigeration, temperature sensitivity, or sterile preparation), they treat complex or chronic conditions, and they are priced at levels that reflect the manufacturer's development costs, limited competition, and pricing leverage in therapeutic categories with few alternatives.

The category includes biologics (drugs derived from living cells, including monoclonal antibodies used in rheumatology, gastroenterology, and oncology), oral oncology agents, medications for rare diseases, HIV antiretrovirals, hepatitis C treatments, and gene therapies. What these medications share economically is that their per-unit costs are high relative to other drug classes, and the patients who take them are concentrated, meaning a small number of employees accounts for a large share of pharmacy plan costs.

In a typical mid-market employer plan, 1 to 3 percent of enrolled members account for 35 to 50 percent of total pharmacy spend. The specific employees in that tier change from year to year as health conditions evolve, but the pattern of concentration is consistent. This concentration is actually an advantage for management purposes: rather than trying to reduce costs spread evenly across the entire enrolled population, specialty drug management programs can focus on the relatively small set of claims that drive the majority of pharmacy costs.

How Specialty Drugs Flow Through the Plan

Specialty drugs reach employees through two primary distribution channels: retail or mail-order specialty pharmacies (the medical benefit's outpatient pharmacy component) and hospital outpatient infusion facilities (the medical benefit's facility component). This two-channel structure creates a split in how costs are tracked and managed that many employers do not fully appreciate until they conduct a detailed claims analysis.

Drugs dispensed through specialty pharmacies are administered as the pharmacy benefit and subject to the pharmacy benefit manager's (PBM) fee schedule and specialty drug list. Drugs administered by infusion in a hospital outpatient facility are processed as the medical benefit and subject to the medical plan's facility rates, which in a traditional group plan are carrier-negotiated rates that can be substantially higher than equivalent specialty pharmacy pricing.

Site-of-care management, one of the highest-impact specialty drug management strategies, specifically targets this channel split by redirecting infusion drugs from hospital outpatient facilities to lower-cost settings such as physician office infusion, independent infusion centers, or home infusion, depending on the drug and patient clinical profile.

The Five Core Specialty Drug Management Strategies

Specialty drug cost management for mid-market employers is most effective when multiple strategies are deployed in coordination rather than as standalone interventions. Each strategy addresses a different element of the cost structure.

1. Site-of-Care Management for Infused Medications

Hospital outpatient departments bill infusion services at rates that can be 200 to 400 percent of the cost of the same infusion delivered in a physician office or independent infusion center. This pricing differential exists because hospital outpatient departments operate under the hospital's charge structure and facility fee billing, which adds cost layers that freestanding infusion facilities do not carry.

For an employer whose plan includes employees receiving infused biologics for conditions such as inflammatory bowel disease, rheumatoid arthritis, or oncology support medications, site-of-care redirection from hospital outpatient to lower-cost settings frequently produces savings of $8,000 to $25,000 per patient per year on the affected claims. The employer's medical plan design can encourage lower-cost sites through differential cost-sharing (lower employee out-of-pocket costs at non-hospital settings) without restricting access to the medication itself.

Clinical criteria for site-of-care redirection typically include: the drug being stable for outpatient administration (not requiring inpatient monitoring), the patient's clinical condition being appropriate for a non-hospital setting, and availability of the appropriate infusion site within a reasonable geographic distance. A care management program or PBM with specialty pharmacy capabilities can automate the identification of site-of-care redirection opportunities at the point of prior authorization renewal.

2. Preferred Specialty Pharmacy Networks

Not all specialty pharmacies charge the same price for the same drug. A preferred specialty pharmacy arrangement contracts specific pharmacies that have agreed to pricing terms that are more favorable to the plan in exchange for exclusive or preferred dispensing of certain specialty drug categories. The economics reflect the pharmacy's interest in high-volume dispensing relationships that guarantee revenue predictability, and the employer's (or PBM's) interest in concentrated volume at negotiated rates.

For employer plans that have the ability to designate preferred specialty pharmacies within their pharmacy benefit design, channeling specialty dispensing through preferred pharmacies typically produces drug acquisition cost savings of 5 to 20 percent on affected claims depending on the drug class and the pharmacy's contracted rate relative to the plan's current cost. Employer plan documents must clearly specify the preferred specialty pharmacy requirements and any cost-sharing differentials that apply to out-of-network specialty dispensing to avoid compliance complications under ACA benefit design rules.

3. Biosimilar Substitution Programs

Biosimilars are biologic drugs that have been determined by the FDA to be highly similar to an already-approved biologic (the reference product) with no clinically meaningful differences in safety, purity, or potency. Biosimilar approvals have accelerated substantially since 2021, with biosimilars now available for several of the most commonly used and most expensive specialty biologics in rheumatology, gastroenterology, and oncology support.

When a patient is currently stabilized on a reference biologic and a biosimilar is clinically appropriate, biosimilar substitution programs can reduce the drug acquisition cost by 15 to 40 percent without changing the patient's therapeutic outcome. The substitution process requires prescriber engagement and sometimes patient education to address concerns about switching from a medication the patient has tolerated well.

The employer's role in biosimilar programs is primarily in plan design: structuring preferred formulary placement and cost-sharing differentials that make biosimilar options more financially attractive for employees relative to reference biologics while maintaining access to reference products when clinically required. Programs that impose penalties on reference biologic access are legally complex and clinically inadvisable. Programs that create positive incentives for biosimilar adoption, including lower employee out-of-pocket costs and prescription drug rewards programs, achieve meaningful substitution rates without restricting access.

4. Prior Authorization and Utilization Management for Specialty

Prior authorization (PA) programs review specialty drug prescriptions against clinical evidence criteria before the plan approves coverage. For specialty drugs, PA programs serve two functions: confirming that the medication is medically necessary for the specific diagnosis and clinical context, and confirming that appropriate step therapy (trying less expensive alternatives first) has been completed when clinically appropriate.

Well-designed specialty PA programs reduce inappropriate specialty drug utilization without creating barriers for patients who need the medications. The quality of a PA program depends on the clinical criteria library (whether criteria reflect current evidence and specialty society guidelines), the turnaround time for decisions, the peer-to-peer review process when initial decisions are unfavorable, and the appeals process for denied requests.

Mid-market employers working through a PBM or specialty benefit management company can access PA programs as a service rather than developing clinical decision-making infrastructure internally. When evaluating a PBM or specialty pharmacy benefit manager, ask specifically about their specialty PA criteria, their approval and denial rates by therapeutic category, and their average time from submission to decision. PA programs that create unnecessary delays or apply criteria that conflict with established clinical guidelines create downstream costs in appeals, emergency care, and employee dissatisfaction that offset pharmacy savings.

5. Manufacturer Assistance and Copay Offset Programs

Pharmaceutical manufacturers offer patient assistance programs (PAPs) and commercial copay assistance cards for many specialty medications. These programs are designed to reduce patient out-of-pocket costs at the point of dispensing. For employer plans, the interaction between manufacturer copay assistance and plan cost-sharing creates a design decision with significant financial implications.

Copay accumulator programs apply the employer plan's full cost-sharing requirements to the patient, preventing manufacturer copay assistance from counting toward the plan's deductible and out-of-pocket maximum. Copay maximizer programs instead capture the full value of the manufacturer's assistance program for the employer plan, reducing the plan's net drug cost while also reducing employee out-of-pocket exposure. The legal and regulatory environment for copay accumulator programs has evolved in recent years, with some states restricting their use, making this an area where compliance review is essential before implementation.

Separately, manufacturer patient assistance programs (PAPs) provide free or steeply discounted specialty medications to patients who meet income eligibility criteria. For employees in lower income brackets who take high-cost specialty medications, connecting them with PAP eligibility review can eliminate pharmacy costs entirely, benefiting both the employee and the plan. A benefits advocacy service or specialty pharmacy with a PAP coordination program can handle this identification and enrollment process without adding HR administrative burden.

Building a Specialty Pharmacy Cost Analysis

Before implementing any specialty drug management program, employers benefit from a structured analysis of their current specialty pharmacy claims to identify where costs are concentrated and which management strategies will produce the greatest return.

Request a specialty drug claims report from your PBM or carrier broken into three dimensions: drug name (or generic equivalent), therapeutic category, and dispensing channel (specialty pharmacy versus medical benefit infusion). This report should cover the prior 24 months of claims to capture the full population of specialty users, including those who have ongoing prescriptions and those who completed treatment.

From this data, calculate the per-member per-year cost for each specialty drug category, the share of total plan costs represented by specialty pharmacy, and the dispensing channel split for infused medications. These three data points identify whether your primary savings opportunity is in site-of-care redirection, biosimilar substitution, preferred pharmacy channeling, or a combination of all three.

The Health Funding Projector includes a pharmacy cost scenario module that allows you to input your current specialty spend distribution and model projected savings under different management program configurations. Running this analysis before requesting vendor proposals gives you an independent savings estimate that you can compare against vendor projections to assess how realistic their assumptions are.

Working with PBMs and Specialty Benefit Managers

Mid-market employers typically access specialty drug management programs through their pharmacy benefit manager (PBM) or through a specialty benefit management company that overlays on top of the existing PBM relationship. The choice between these two models affects the breadth of interventions available, the pricing transparency, and the ongoing administrative relationship.

PBM-integrated specialty programs offer operational simplicity: one vendor relationship handles both standard pharmacy and specialty pharmacy management, with integrated claims data and a single reporting interface. The limitation is that large PBMs sometimes have rebate arrangements with pharmaceutical manufacturers that create financial incentives to favor specific specialty drugs over lower-cost alternatives, including biosimilars that carry lower rebates. Employers who access specialty programs through their PBM should request transparent pass-through rebate terms and verify that the PBM's preferred formulary positioning reflects clinical evidence rather than rebate economics.

Independent specialty benefit managers operate separately from PBMs and often offer clinical management programs with stronger evidence-based protocols, more aggressive biosimilar and site-of-care programs, and greater pricing transparency. They require coordination with the existing PBM for data integration and claims processing, which adds administrative touchpoints. For employers whose PBM specialty program is not producing meaningful savings or whose specialty costs are growing faster than medical trend, an independent specialty benefit manager evaluation is worth the investment.

Compliance Considerations for Specialty Drug Management

Several regulatory requirements affect how employers can structure specialty drug management programs in their health plans, and understanding them prevents designs that create legal exposure rather than savings.

The ACA's essential health benefits requirements apply to small group plans and prohibit annual or lifetime dollar limits on essential health benefits, which include prescription drug coverage. Employer plans cannot apply blanket specialty drug caps or exclusions that function as de facto lifetime limits. Management programs must be designed to promote appropriate utilization and cost-effective care navigation, not to deny access to medically necessary specialty medications.

The Mental Health Parity and Addiction Equity Act (MHPAEA) requires that nonquantitative treatment limitations applied to mental health and substance use disorder benefits be no more restrictive than those applied to medical and surgical benefits. Prior authorization requirements applied to specialty behavioral health medications (such as long-acting injectable antipsychotics or medications used in substance use disorder treatment) must comply with parity analysis requirements. Employers implementing new PA programs for specialty medications should have a parity analysis completed by their broker or TPA before implementation.

ERISA fiduciary obligations require that plan administrators act prudently and in the interest of plan participants. Implementing specialty drug management programs that are structured primarily to maximize employer cost savings at the expense of patient clinical outcomes creates fiduciary risk. Programs that offer clinically sound cost management while maintaining patient access to medically necessary care are well within the scope of prudent plan administration.

Internal Links and Related Tools

Specialty drug management connects to broader pharmacy benefit strategy, which the pharmacy benefit management guide covers comprehensively including PBM contract structure and rebate pass-through terms. The self-funded TPA selection guide is relevant for employers considering self-funding as the structural framework that makes specialty drug management programs most accessible and financially transparent. The stop-loss coverage guide for self-funded plans explains how high-cost specialty drug claims interact with individual stop-loss attachments and how to structure stop-loss coverage appropriately when specialty drug exposure is a known risk.

Related Reading

For additional context on pharmacy benefits and health plan cost management, explore these related Benefitra articles:

• Pharmacy Benefit Management for Employer Health Plans: What Employers Need to Know
• Self-Funded Health Plans and TPA Selection: What Every Mid-Market Employer Needs to Know
• Stop-Loss Coverage for Self-Funded Health Plans: Employer Guide

Frequently Asked Questions

How do I know if specialty drugs are a significant cost driver for my health plan?

Request a claims distribution report from your PBM or carrier and calculate the percentage of total pharmacy spend attributable to specialty drugs (typically defined as drugs on your PBM's specialty drug list). If that percentage exceeds 25 percent and your plan has more than 50 enrolled lives, specialty drug management programs are worth a structured evaluation. For plans with fewer than 50 enrolled lives, specialty costs are more variable year to year, but a single high-cost specialty user can still justify proactive management infrastructure.

What is the difference between step therapy and prior authorization?

Prior authorization is a broader clinical review process that determines whether a drug is medically necessary for the patient's specific diagnosis and clinical situation. Step therapy is a specific type of utilization management within prior authorization that requires documentation that clinically appropriate lower-cost alternatives have been tried and failed before the plan approves a higher-cost specialty medication. Step therapy is appropriate for therapeutic categories where less expensive alternatives have comparable clinical evidence, and it is generally not appropriate for situations where clinical guidelines recommend the specialty drug as the first-line standard of care.

Can employees appeal specialty drug prior authorization denials?

Yes. ERISA requires that employer health plans provide a claims and appeals process that gives members a meaningful opportunity to contest coverage denials. For specialty drug prior authorization denials, employees have the right to an internal appeal and, in most cases, an independent external review. Plans that implement specialty PA programs must maintain a functioning appeals process with reasonable turnaround times. Emergency or urgent care situations involving specialty medications may qualify for expedited review timelines under ERISA claims procedure regulations.

Are biosimilars safe to use in place of reference biologics?

The FDA approval standard for biosimilars requires demonstration that the biosimilar has no clinically meaningful differences in safety, purity, or potency compared to the reference product. Major medical and pharmacy specialty societies including the American College of Rheumatology, the Crohn's and Colitis Foundation, and the American Society of Clinical Oncology support biosimilar use as clinically appropriate for most indications. Patient concerns about switching are legitimate and should be addressed through prescriber conversations and pharmacist counseling, but clinical evidence does not support the concern that switching stable patients to biosimilars produces worse outcomes.

How do specialty drug costs affect stop-loss coverage premiums?

Known high-cost specialty drug users are a significant consideration for stop-loss underwriting. Self-funded employers with employees on gene therapies or other catastrophic-cost specialty medications should discuss specific accommodation, carve-out, or laser provisions with their stop-loss carrier at the time of coverage placement. Failing to disclose known high-cost claimants during the underwriting process creates coverage disputes at claims time and may result in denial of stop-loss coverage for affected claims. Transparency with stop-loss underwriters about known specialty drug exposure is both ethically required and practically necessary for the stop-loss relationship to function as intended.